Expanding Horizons for Nucleic-Acid-Based Therapeutics
Nucleic-acid-based drugs are revolutionizing biopharma, attracting significant investments as companies explore their potential to regulate disease pathways. With platforms like antisense oligonucleotides (ASOs) and small-interfering RNAs (siRNAs) validated through multiple FDA approvals, the next wave of innovation is here.
- Precision Medicine: Roche’s $2B partnership with MOMA Therapeutics taps into next-generation precision oncology tools targeting challenging enzymes.
- Broader Therapeutics: Eli Lilly’s $3.2B acquisition of Morphic advances oral integrin inhibitors, while AstraZeneca’s $2B deal with CSPC drives cardiovascular innovation
Emerging Opportunities
Despite challenges in delivery to non-liver tissues, innovative strategies are emerging on Delivery technologies and RNA targets. As innovation broadens the application scope, nucleic-acid-based drugs are positioned to redefine therapeutic landscapes, tackling diverse diseases and unmet needs. View the full article here.
Attract top-tier attention by aligning your brand with this growing market. Partner with us to showcase your solutions to C-suite leaders and innovators in the biotech and biopharma industries. Contact us.
About Biopharma Dealmakers
Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals, and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles.
The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.
